Physician profile
Matthew Seena Hamedani
NPI 1538592654
$11,253.86
in general payments reported to CMS, 2019-2025
12 companies · $4,467 in 2025
The $4,467 reported for 2025 was more than what 96% of Oral & Maxillofacial Surgery providers received nationally (typical 2025 total: $184).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $520 · 2021: $1,696 · 2022: $2,578 · 2023: $715 · 2024: $629 · 2025: $4,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,373 · Food and Beverage: $2,388 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,373.13 |
| Food and Beverage | $2,387.93 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohorizons Implant Systems INC. | $6,661.78 | 2019-2025 | Biohorizons, Biohorizons Dental Implants |
| Zimmer Biomet Holdings, INC. | $2,514.44 | 2019-2022 | |
| Straumann USA LLC | $606.60 | 2020-2025 | |
| Nobel Biocare USA | $462.64 | 2019-2022 | |
| Zimvie INC. | $304.67 | 2022-2025 | |
| Keystone Dental INC. | $280.52 | 2022-2024 | |
| Stryker Corporation | $139.91 | 2022 | |
| Dentsply Sirona INC | $111.39 | 2019-2024 | Waveone Gold Conform Fit |
| Tulsa Dental Products LLC | $111.00 | 2019 | |
| Vyne Pharmaceuticals INC. | $24.81 | 2020 | |
| Sonendo INC | $19.43 | 2023 | Gentlewave G4 Console |
| Orapharma, A Division of Bausch Health US, LLC | $16.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hamedani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.